Sanfilippo syndrome market to approach $15.01 billion by 2030

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Sanfilippo Syndrome Market Between 2026 And 2030?

The sanfilippo syndrome market size has seen substantial growth in recent years. It is anticipated to increase from $9.21 billion in 2025 to $10.18 billion in 2026, at a compound annual growth rate (CAGR) of 10.5%. The expansion witnessed in prior periods can be attributed to several factors, including the restricted treatment options available for sanfilippo syndrome, a growing understanding of lysosomal storage disorders, the proliferation of rare disease advocacy groups, incremental improvements in diagnostic capabilities, and initial funding for research into orphan diseases.

The market size for sanfilippo syndrome is projected to experience significant expansion in the coming years. It is forecast to climb to $15.02 billion by 2030, achieving a compound annual growth rate (CAGR) of 10.2%. This growth during the forecast period can be attributed to advancements in AAV-based gene therapies, an increase in orphan drug designations and incentives, rising healthcare expenditure on rare diseases, expanding newborn screening initiatives, and growing investment from biotech and pharmaceutical companies. Prominent trends anticipated in the forecast period involve a surge in clinical trial activity for sanfilippo syndrome treatments, the increasing adoption of gene therapy approaches in pediatric neurodegenerative disorders, a rise in the use of advanced diagnostic techniques for early detection, the expansion of compassionate use and early access programs for rare diseases, and enhanced collaboration between biotech firms and research institutions.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23507&type=smp

Which Strong Drivers Are Impacting The Sanfilippo Syndrome Market Growth?

A growing emphasis on gene therapies is projected to fuel the expansion of the sanfilippo syndrome market in the future. These therapies involve medical interventions designed to alter or substitute defective genes, aiming to cure or avert illnesses. This heightened attention stems from their capability to address genetic disorders, rare ailments, and long-term conditions by pinpointing the underlying cause at a molecular level. Specifically for Sanfilippo syndrome, gene therapies assist by introducing working versions of the faulty gene, thereby restoring enzyme output and diminishing the buildup of detrimental substances within cells. As an illustration, in April 2024, the American Society of Gene & Cell Therapy, a US-based non-profit medical and scientific organization, indicated that phase III clinical trials for gene therapy saw a 10% increase in Q4 2023, representing the initial quarterly rise since Q3 2022. Consequently, the growing attention to gene therapies is stimulating the expansion of the sanfilippo syndrome market.

Which Segment Types Are Examined In The Sanfilippo Syndrome Market Segment Study?

The sanfilippo syndrome market covered in this report is segmented –

1) By Treatment: Enzyme Replacement Therapy, Gene Therapy, Genistein, Other Treatments

2) By Diagnosis: Glycosaminoglycan Analysis (GAG Analysis), Genomic Deoxyribonucleic Acid Sequencing (Genomic DNA Sequencing), Activity Assay, Other Diagnosis

3) By End-User: Hospitals, Research Institutions

Subsegments:

1) By Enzyme Replacement Therapy: Intravenous Enzyme Replacement Therapy, Intrathecal Enzyme Replacement Therapy, Intracerebroventricular (ICV) Enzyme Replacement Therapy

2) By Gene Therapy: Adeno-Associated Virus (AAV)-Based In Vivo Gene Therapy, Lentiviral Vector–Based Ex Vivo Gene Therapy, Non-Viral Vector Gene Delivery

3) By Genistein: Oral Genistein Supplementation, High-Dose Genistein Regimens, Low-Dose Genistein Regimens

4) By Other Treatments: Substrate Reduction Therapy (SRT), Stem Cell Therapy, Anti-Inflammatory Agents, Symptomatic Management Drugs

Which Trends Are Contributing To Changes In The Sanfilippo Syndrome Market?

Major companies operating in the sanfilippo syndrome market are prioritizing the development of innovative treatments, such as gene therapies, to enhance patient outcomes and slow the disease’s progression. Gene therapy represents a medical methodology that employs genes to prevent, treat, or cure diseases by correcting or replacing faulty genes in the body. For instance, in February 2025, Ultragenyx Pharmaceutical Inc., a US-based biopharmaceutical company, announced new findings concerning UX111 (ABO-102), an AAV gene therapy for sanfilippo syndrome Type A (MPS IIIA). This treatment demonstrated statistically significant improvements in Bayley-III raw scores for cognition, receptive communication, and expressive communication. Furthermore, it achieved a substantial and sustained reduction in cerebrospinal fluid (CSF) heparan sulfate (HS) levels, which correlated with improved clinical outcomes.

Which Players Are Part Of The Competitive Landscape Of The Sanfilippo Syndrome Market?

Major companies operating in the sanfilippo syndrome market are Takeda Pharmaceutical Company Limited, BioMarin Pharmaceutical Inc, Ultragenyx Pharmaceutical Inc, JCR Pharmaceuticals Co Ltd, Denali Therapeutics Inc, REGENXBIO Inc, Greenwood Genetic Center, ArmaGen Inc, Abeona Therapeutics Inc, Orchard Therapeutics plc, Allievex Corporation, Lysogene SA, Sio Gene Therapies Inc, Abeona Therapeutics Europe, Spark Therapeutics Inc, PTC Therapeutics Inc, Neurogene Inc, Taysha Gene Therapies Inc, MeiraGTx Holdings plc, Sangamo Therapeutics Inc, Freeline Therapeutics Holdings plc, LogicBio Therapeutics Inc

Get The Full Sanfilippo Syndrome Market Report:

https://www.thebusinessresearchcompany.com/report/sanfilippo-syndrome-global-market-report

Which Region Accounts For The Largest Portion Of The Sanfilippo Syndrome Market?

North America was the largest region in the sanfilippo syndrome market in 2025. The regions covered in the sanfilippo syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Sanfilippo Syndrome Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/sanfilippo-syndrome-global-market-report

Browse Through More Reports Similar to the Global Sanfilippo Syndrome Market 2026, By The Business Research Company

Antiphospholipid Syndrome Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/antiphospholipid-syndrome-treatment-global-market-report

Polycystic Ovarian Syndrome Treatment Market Report

https://www.thebusinessresearchcompany.com/report/polycystic-ovarian-syndrome-treatment-global-market-report

Dry Eye Syndrome Market Report

https://www.thebusinessresearchcompany.com/report/dry-eye-syndrome-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795